Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization - Intangibles: 2010-2011

Historic Amortization - Intangibles for Arrowhead Pharmaceuticals (ARWR) over the last 2 years, with Dec 2011 value amounting to $71,618.

  • Arrowhead Pharmaceuticals' Amortization - Intangibles rose 18.47% to $71,618 in Q4 2011 from the same period last year, while for Dec 2011 it was -$1.4 million, marking a year-over-year change of. This contributed to the annual value of $241,808 for FY2011, which is negligibly% changed negligibly from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Amortization - Intangibles stood at $71,618 for Q4 2011, which was up 104.47% from -$1.6 million recorded in Q3 2011.
  • In the past 5 years, Arrowhead Pharmaceuticals' Amortization - Intangibles ranged from a high of $71,618 in Q4 2011 and a low of -$1.6 million during Q3 2011.
  • Over the past 2 years, Arrowhead Pharmaceuticals' median Amortization - Intangibles value was $60,452 (recorded in 2011), while the average stood at -$214,527.
  • Within the past 5 years, the most significant YoY rise in Arrowhead Pharmaceuticals' Amortization - Intangibles was 18.47% (2011), while the steepest drop was 2,747.70% (2011).
  • Quarterly analysis of 2 years shows Arrowhead Pharmaceuticals' Amortization - Intangibles stood at $60,452 in 2010, then increased by 18.47% to $71,618 in 2011.
  • Its last three reported values are $71,618 in Q4 2011, -$1.6 million for Q3 2011, and $60,452 during Q2 2011.